Neurocrine Biosciences, Inc. (NBIX)

CTI BioPharma Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jul 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	12,718	13,820	12,946	11,482	8,080	8,955
Market Cap Growth	-10.24%	6.75%	12.75%	42.11%	-9.78%	-9.54%
Enterprise Value	12,232	12,878	12,124	10,966	7,766	8,528
Last Close Price	128.23	136.50	131.76	119.44	85.17	95.85
PE Ratio	37.81	40.49	51.85	74.32	90.18	21.99
Forward PE	14.91	18.15	21.34	22.53	24.55	22.30
PS Ratio	5.10	5.87	6.86	7.71	7.13	8.56
PB Ratio	4.71	5.34	5.80	6.72	5.88	7.95
P/TBV Ratio	4.79	5.43	5.91	6.90	5.88	7.95
P/FCF Ratio	24.06	24.80	35.80	35.56	34.66	41.15
P/OCF Ratio	22.42	23.21	33.20	33.83	31.50	39.19
PEG Ratio	1.18	0.37	0.37	0.37	0.37	0.37
EV/Sales Ratio	4.87	5.47	6.43	7.37	6.85	8.15
EV/EBITDA Ratio	23.18	21.11	29.14	41.44	35.51	25.37
EV/EBIT Ratio	24.51	22.09	30.71	44.04	37.38	26.04
EV/FCF Ratio	23.14	23.11	33.53	33.96	33.32	39.19
Debt / Equity Ratio	0.18	0.19	0.19	0.15	0.32	0.37
Debt / EBITDA Ratio	0.84	0.76	0.99	0.94	1.88	1.19
Debt / FCF Ratio	0.93	0.89	1.19	0.81	1.89	1.90
Asset Turnover	0.70	0.68	0.67	0.67	0.60	0.69
Inventory Turnover	18.63	15.99	16.48	14.85	11.71	12.59
Quick Ratio	2.88	3.06	2.25	2.49	3.65	5.14
Current Ratio	3.20	3.40	2.45	2.70	3.96	5.45
Return on Equity (ROE)	13.39%	14.16%	12.68%	10.03%	7.17%	46.20%
Return on Assets (ROA)	8.67%	10.46%	8.78%	7.01%	6.82%	13.46%
Return on Capital (ROIC)	10.42%	12.68%	10.66%	8.22%	7.75%	15.33%
Return on Capital Employed (ROCE)	14.90%	18.20%	15.20%	13.60%	11.40%	21.20%
Earnings Yield	2.74%	2.47%	1.93%	1.35%	1.11%	4.55%
FCF Yield	4.16%	4.03%	2.79%	2.81%	2.89%	2.43%
Buyback Yield / Dilution	0.05%	-2.67%	-2.12%	-1.02%	-0.10%	-2.19%

Updated Jul 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q